Taiga Nishihori

Oncology

12902 Usf Magnolia Dr
Tampa, FL 33612

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 284 publications

Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.

Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.

Journal: Blood cancer journal

Published: August 31, 2026

Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Practice Guidelines From the American Society for Transplantation and Cellular Therapy.

Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Practice Guidelines From the American Society for Transplantation and Cellular Therapy.

Journal: Transplantation and cellular therapy

Published: August 10, 2026

HSR26-263: Development of an Outcomes Prediction Web Application for Allogeneic Transplant in Acute Lymphoblastic Leukemia.

HSR26-263: Development of an Outcomes Prediction Web Application for Allogeneic Transplant in Acute Lymphoblastic Leukemia.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes.

Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes.

Journal: Transplantation and cellular therapy

Published: April 15, 2026

Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes.

Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes.

Journal: Transplantation and cellular therapy

Published: April 15, 2026

Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis.

Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis.

Journal: Blood advances

Published: April 08, 2026

Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.

Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.

Journal: Transplantation and cellular therapy

Published: April 03, 2026

HSR26-263: Development of an Outcomes Prediction Web Application for Allogeneic Transplant in Acute Lymphoblastic Leukemia.

HSR26-263: Development of an Outcomes Prediction Web Application for Allogeneic Transplant in Acute Lymphoblastic Leukemia.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 31, 2026

Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple Myeloma.

Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple Myeloma.

Journal: Cancer research

Published: March 10, 2026

Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.

Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.

Journal: Transplantation and cellular therapy

Published: February 12, 2026

Single center evaluation of a composite risk assessment model to predict non-relapse mortality following allogeneic hematopoietic cell transplantation (HCT).

Single center evaluation of a composite risk assessment model to predict non-relapse mortality following allogeneic hematopoietic cell transplantation (HCT).

Journal: Bone marrow transplantation

Published: January 13, 2026

A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma.

A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma.

Journal: Bone marrow transplantation

Published: December 18, 2025

Showing 1-12 of 284

Last Updated: 09/26/2026